With fears over manufacturing costs and future investment, here’s what firms are doingThe carmakers’ road to BrexitHow prepared are aerospace and defence firms?Brexit poses a big threat to pharmaceutical research and manufacturing in the UK, the industry has said, potentially driving up manufacturing costs and deterring future investment.AstraZeneca and other companies have frozen all manufacturing investments. Britain’s second-biggest drugmaker decided to halt further investments at its Macclesfield site in the summer of 2017. Its chairman, Leif Johansson, has said the UK needs to make sure it “does not become an isolated island in the middle of the Atlantic Ocean”. Continue reading...
Swiss company is stockpiling amid concerns about the supply and safety of medicinesThe Swiss pharmaceuticals company Novartis has said it is stockpiling drugs in the UK before a possible no-deal Brexit, which it warned would be “hugely impactful” for patients.Firms across the economy are bracing for the possibility of the UK leaving the EU on 29 March without a deal after parliament resoundingly rejected Theresa May’s withdrawal agreement. Continue reading...
По мнению представителей компании, лучший способ вылечить рак — это не заболеть им. И появление такого универсального защитного средства возможно уже в ближайшее время. Есть только одна проблема, которая может задержать его выход на рынок, […] Сообщение Novartis создает препарат, исключающий заболевание раком появились сначала на ХВИЛЯ.
Novartis (NVS) gains the EU approval for MS drug Gilenya for children who are 10-17 years old with relapsing-remitting forms of multiple sclerosis.
Ophthotech (OPHT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cohen allegedly lied to Congress about a potential Trump Tower in Moscow during the 2016 election.
Teva (TEVA) and partner Celltrion get FDA nod for approval of their biosimilar to Roche's Rituxan in three Non-Hodgkin's lymphoma indications.
Novartis CEO Vas Narasimhan On The Price Of Gene Therapies: 'It's A Challenge We Have To Solve'
In May Novartis announced that it had acquired the gene therapy pioneer AveXis in a $8.7 billion deal, but according to the the Swiss drug giant CEO Vas Narasimhan, he wishes he could have bought the company much earlier.
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Roche (RHHBY) is all set to acquire biotech Jecure Therapeutics, which focuses on the discovery of novel therapeutics for the treatment of NASH and liver fibrosis.
The large-cap pharma industry has been on a strong footing lately. Here are four stocks from the space that investors may consider betting on.
Novartis (NVS) obtains EC approval for Ziextenzo, the biosimilar of Amgen's Neulasta.
Celgene (CELG) and partner bluebird complete enrollment in a phase II study for CAR T cell therapy candidate, bb2121 for patients with relapsed and refractory multiple myeloma.
Teva (TEVA) launches the first approved generic version of Mylan's (MYL) popular EpiPen (epinephrine) auto-injector for severe allergy treatment in the United States.
Per a Financial Times report, Glaxo (GSK) is in exclusive talks with Unilever to sell its Horlicks brand in India. Another report in an India-based newspaper says Nestle is close to buying Horlicks.
Pipeline and regulatory updates are the key highlights in the biotech sector this week.
Швейцарский фармацевт Roche планирует приобрести американскую компанию Jecure Therapeutics с целью расширения бизнеса в сфере производства препаратов для лечения стеатоза печени. Представители компании не уточнили, какую сумму она готова заплатить за американскую фирму. Стоит отметить, что другие крупные представители фармацевтического сектора, в частности, Pfizer, Gilead Sciences и Novartis, в последнее время тоже заключили ряд сделок, направленных на расширение бизнеса в сфере лечения названного выше заболевания.
Two-thirds of treatments identified by WHO yet to be developed, says monitor groupThe world’s biggest pharmaceutical firms have failed to develop two-thirds of the 139 urgently needed treatments in developing countries, according to an independent report, which highlights the need for medicines including an infants’ vaccine for cholera.The report by the Access to Medicine Foundation, which monitors 20 major drugs companies and the availability of their medicines in low to middle income countries, found that most firms focus on infectious diseases such as HIV/Aids, malaria and tuberculosis but had failed to focus on other serious ailments. Continue reading...
Swiss pharmaceutical firm announces it will leave north-east site by 2020, in move not linked to BrexitNovartis has put around 400 jobs at risk at its Grimsby factory as the Swiss pharmaceutical firm embarks on a major cost-cutting drive.The group said on Tuesday that it will vacate the manufacturing site in north-east Lincolnshire by 2020 as it also announced stinging job cuts in Switzerland. Continue reading...